At a glance
All energies detected1
Expand your routine / theranostics procedures and research into new therapies
>2.5 X sensitivity2
Scan without trade-offs between ultra-high sensitivity and excellent resolution
Exceptional versatility
Fast, static and dynamic SPECT and advanced CT from an all-in-one 4D SPECT/CT
<3-sec collimator exchange
Low/medium or high energy collimation is automatically selected by the system
Don't trade out collimators anymore
< 3 seconds is all it takes to go from low/medium to high energy scans
Focus on patients and leave auto collimator selection to StarGuide GX
Our collimators fundamentally transform daily workflow efficiencies
Molded lead collimators typically have imperfections. GE HealthCare uses high-quality and consistent additive manufacturing to produce StarGuide GX collimators made of tungsten for great precision in hole shape, hole size and CZT pixel registration. Tungsten’s superior density over lead minimizes gamma penetration, helping deliver clearer, more accurate SPECT images. Lowering septa penetration background noise is important for enhancing contrast and image quality. Clinicians can have greater confidence that the detected signals were emitted from the radiopharmaceutical’s actual location.
StarGuide GX features MIM Software’s advanced quantitative reconstruction and segmentation for dosimetry and treatment monitoring.
LesionID® Pro
Aids in decision making, therapy response monitoring, and automated lesion segmentation, including AI-enabled segmentation for physiological uptake removal
MIM SurePlanTM MRT
AI-aided organ segmentation for single- and multi-timepoint voxel-based dosimetry
MIM Encore®
All-in-one, integrated post-processing and analysis productivity hub with an extensive toolkit to support theranostics
References
1. Up to 500 KeV
2. Improved sensitivity: StarGuide GX with Low-Med Energy collimator compared to NM/CT 870 DR with LEHRS collimator. Based on system volume sensitivity measured per NEMA NU-1 2023, with adaptations for StarGuide GX.
3. Improved energy resolution: StarGuide GX with Low-Med Energy collimator compared to NM/CT 870 DR with LEHRS collimator. Energy resolution measured per NEMA NU-1 2023 using 99mTc and with adaptations for StarGuide GX.
4. Improved spatial resolution: StarGuide GX with Low-Medium Energy collimator compared to NM/CT 870 DR with LEHRS collimator. SPECT resolution with scatter measured per NEMA NU-1 2023 using 99mTc and with adaptations for StarGuide GX. SPECT reconstruction used clinical bone reconstruction. Central, Radial, and Tangential
5. Improved volume sensitivity: StarGuide GX with Low-Med Energy collimator compared to NM/CT 870 DR with LEHRS collimator. System volume sensitivity measured per NEMA NU-1 2023, with adaptations for StarGuide GX.
6A. Growth projections from Frost & Sullivan.
6B. MEDraysintell 2021; Link: U.S. Healthcare Professionals site.
6C. Therapies and radiopharmaceuticals may be in clinical trial and/or not approved in all countries. Regulatory status should be confirmed with the relevant authority in each country.
7A. ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability).
7B. In clinical practice, the use of ASiR-V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR-V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
8. Using overlapped reconstruction
9. As compared to NM/CT 870 DR with Optima 540 CT
*StarGuide GX is CE marked. Not approved or cleared by the US FDA. Not available for sale in the United States.